Cian Healthcare Limited

Classified as a pharmaceutical company, the entity is currently in a restart phase following the National Company Law Tribunal, Mumbai Bench's approval of its Resolution Plan on December 18, 2025 under the Insolvency and Bankruptcy Code, 2016. New management took over on February 1, 2026, with Ananta Medicare Limited becoming the holding company (55% stake), and Mr. Pradeep Kumar Jain as the successful resolution applicant. Operations are being rebuilt — revenue for the half-year ending March 31, 2026 stood at ₹106.61 lakhs, indicating very low business activity as the company resumes. The cost structure is materials-heavy at 58.9% of revenue, which is consistent with pharmaceutical manufacturing inputs, alongside employee costs at 20.8% and other operating expenses at 24.1%. The company reported a net loss of ₹1,499.51 lakhs for FY26, including exceptional items such as inventory revaluation losses of ₹1,353.73 lakhs and a GST write-off of ₹347.28 lakhs. The auditors issued a qualified opinion citing unconfirmed trade receivables, unverifiable PPE and inventory values, and inadequate internal financial controls. The equity capital expanded 20-fold from ₹1.25 crore to ₹25 crore through a March 2026 preferential allotment, with the promoter group holding 95% post-allotment.